Solar Pharma posts 16.5% rise in Q3 web revenue, declares dividend of Rs 8.50/share

Published on

Advertisement

[ad_1]

MUMBAI: Solar Pharmaceutical Industries Ltd on Wednesday reported a 16.52 per cent rise in web revenue at Rs 2, 523.75 crore for the October-December quarter of the present monetary yr on the again of robust gross sales within the home and US markets.

The corporate had reported a web revenue of Rs 2, 166.01 crore in the identical interval of the earlier fiscal.

The pharma main’s board has declared an interim dividend of Rs 8.50 per share for 2023-24, up from Rs 7.50 per share interim dividend for the earlier yr.

The corporate’s income from operations rose 10 per cent to Rs 12, 381 crore within the December quarter.

Solar Prescribed drugs Managing Director Dilip Shanghvi stated, “We’re happy by our continued broad-based progress, together with in world specialty. We’re keenly trying ahead to EMA submitting of Nidlegy within the coming months. As soon as authorised, Nidlegy will considerably broaden our onco-derm franchise in Europe.”

The corporate’s share value shot up 4.88 per cent after the outcomes to cross a one-year excessive at Rs 1, 438.50.

[ad_2]

Latest articles

SIR Controversy: Over 1.13 Lakh New Voter Entries in Bengaluru Have No Traceable Application Records

BENGALURU: A fresh controversy has emerged over the Special Intensive Revision (SIR) of electoral...

Trump, Xi and Putin Prepare for Historic Three-Way Summit in China

The world is preparing for a significant diplomatic moment as United States President Donald...

Ukraine-Russia Peace Talks Enter Second Day as Territorial Disputes Remain Major Obstacle

Peace negotiations between Ukraine and Russia entered their second day in Abu Dhabi on...

Delhi Pollution Crisis Deepens as AQI Reaches 324, GRAP-II Restrictions Come Into Force

Delhi's air pollution crisis has intensified with the national capital's Air Quality Index (AQI)...
Advertisement
Advertisement